Compare Stocks: NVO, LLY, and SKYE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LLY Eli Lilly and Company	$1,147.06 -1.1%	$1,191.71	$712.05 ▼ $1,292.65	$1.08T	0.5	2.50 million shs	2.22 million shs
NVO Novo Nordisk A/S	$46.59 -1.9%	$47.93	$35.12 ▼ $64.16	$208.07B	0.74	10.83 million shs	6.21 million shs
SKYE Skye Bioscience	$1.86 +4.5%	$4.12	$1.64 ▼ $39.92	$8.24M	2.9	184,916 shs	182,857 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LLY Eli Lilly and Company	0.00%	-1.88%	-3.76%	+1.23%	+55.79%
NVO Novo Nordisk A/S	0.00%	+2.19%	+1.49%	+8.54%	-17.91%
SKYE Skye Bioscience	0.00%	+4.79%	-50.71%	-68.29%	-93.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LLY Eli Lilly and Company	$1,147.06 -1.1%	$1,191.71	$712.05 ▼ $1,292.65	$1.08T	0.5	2.50 million shs	2.22 million shs
NVO Novo Nordisk A/S	$46.59 -1.9%	$47.93	$35.12 ▼ $64.16	$208.07B	0.74	10.83 million shs	6.21 million shs
SKYE Skye Bioscience	$1.86 +4.5%	$4.12	$1.64 ▼ $39.92	$8.24M	2.9	184,916 shs	182,857 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LLY Eli Lilly and Company	0.00%	-1.88%	-3.76%	+1.23%	+55.79%
NVO Novo Nordisk A/S	0.00%	+2.19%	+1.49%	+8.54%	-17.91%
SKYE Skye Bioscience	0.00%	+4.79%	-50.71%	-68.29%	-93.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LLY Eli Lilly and Company	2.83	Moderate Buy	$1,292.18	12.65% Upside
NVO Novo Nordisk A/S	2.16	Hold	$64.94	39.38% Upside
SKYE Skye Bioscience	2.20	Hold	$64.00	3,340.86% Upside

Current Analyst Ratings Breakdown

Latest NVO, LLY, and SKYE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	LLY Eli Lilly and Company	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform ➝ Buy
8/27/2026	SKYE Skye Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	NVO Novo Nordisk A/S	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Sell
8/26/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/12/2026	NVO Novo Nordisk A/S	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$47.00
8/12/2026	NVO Novo Nordisk A/S	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/11/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/11/2026	NVO Novo Nordisk A/S	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2026	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$1,376.00
8/7/2026	LLY Eli Lilly and Company	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,370.00 ➝ $1,376.00
8/6/2026	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$1,419.00

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LLY Eli Lilly and Company	$65.18B	16.57	$25.09 per share	45.72	$28.07 per share	40.86
NVO Novo Nordisk A/S	$46.80B	4.45	$4.69 per share	9.94	$6.58 per share	7.08
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$5.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LLY Eli Lilly and Company	$20.64B	$29.80	38.49	24.97	1.42	33.53%	97.83%	23.23%	10/29/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.09	11.39	13.62	1.56	35.36%	61.20%	21.49%	11/4/2026 (Estimated)
SKYE Skye Bioscience	-$55.92M	-$10.16	N/A	N/A	N/A	N/A	-329.08%	-201.79%	N/A

Latest NVO, LLY, and SKYE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	SKYE Skye Bioscience	-$0.29	-$0.27	+$0.02	-$2.4550	N/A	N/A
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.40	$8.38	+$1.98	$7.94	$20.82 billion	$22.97 billion
8/5/2026	Q2 2026	NVO Novo Nordisk A/S	$0.77	$0.96	+$0.19	$0.72	$10.89 billion	$11.98 billion
6/30/2026	Q2 2026	NVO Novo Nordisk A/S	N/A	$0.9440	N/A	$0.72	N/A	$11.98 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LLY Eli Lilly and Company	$6.92	0.60%	+15.18%	23.22%	11 Years
NVO Novo Nordisk A/S	$0.82	1.76%	+21.74%	20.05%	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Latest NVO, LLY, and SKYE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/22/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.59%	8/14/2026	8/14/2026	9/10/2026
8/5/2026	NVO Novo Nordisk A/S		$0.5786	2.58%	8/17/2026	8/17/2026	8/25/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LLY Eli Lilly and Company	1.41	1.35	1.00
NVO Novo Nordisk A/S	0.59	0.79	0.56
SKYE Skye Bioscience	N/A	0.95	0.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%
SKYE Skye Bioscience	6.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LLY Eli Lilly and Company	50,000	941.36 million	940.04 million	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
SKYE Skye Bioscience	11	4.43 million	4.15 million	Optionable

NVO, LLY, and SKYE Headlines

Recent News About These Companies

Skye Bioscience (SKYE) shares rise 6% after hours: Here's what's driving the move

August 26, 2026 | msn.com

Skye Bioscience (NASDAQ:SKYE) Director Sells 68,140 Shares

August 21, 2026 | insidertrades.com

Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript

August 14, 2026 | seekingalpha.com

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

August 14, 2026 | globenewswire.com

Pomerantz LLP Commences Class Action Against Skye Bioscience, Inc. – SKYE

July 12, 2026 | natlawreview.comN

Cadrenal Therapeutics Names Sharp Interim CFO

June 29, 2026 | marketwatch.com

Skye Bioscience Expands Authorized Shares After Shareholder Approval

May 29, 2026 | tipranks.com

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

May 20, 2026 | globenewswire.com

Skye Bioscience (SKYE) price target decreased by 11.48% to 7.87

May 14, 2026 | msn.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (SKYE)

May 14, 2026 | theglobeandmail.com

Skye Bioscience, Inc.: Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 14, 2026 | finanznachrichten.de

Pomerantz LLP Files Investor Lawsuit Against Skye Bioscience, Inc. – SKYE

May 13, 2026 | natlawreview.comN

Skye Bioscience Initiates CBeyond™ Expansion Study (Part C) with Planned Review on May 18, 2026

May 12, 2026 | quiverquant.comQ

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 12, 2026 | globenewswire.com

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 11, 2026 | globenewswire.com

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

April 22, 2026 | globenewswire.com

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

April 7, 2026 | globenewswire.com

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

April 2, 2026 | globenewswire.com

Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...

March 11, 2026 | finance.yahoo.com

Skye Bioscience, Inc.: Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 11, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVO, LLY, and SKYE Company Descriptions

Eli Lilly and Company NYSE:LLY

$1,147.06 -12.54 (-1.08%)

As of 09/4/2026 03:58 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$46.59 -0.92 (-1.94%)

As of 09/4/2026 03:58 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Skye Bioscience NASDAQ:SKYE

$1.86 +0.08 (+4.49%)

As of 09/4/2026 04:00 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVO, LLY, and SKYE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVO, LLY, and SKYE Earnings

Compare Dividends

Latest NVO, LLY, and SKYE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVO, LLY, and SKYE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVO, LLY, and SKYE Company Descriptions

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

Skye Bioscience NASDAQ:SKYE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVO, LLY, and SKYE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVO, LLY, and SKYE Earnings

Compare Dividends

Latest NVO, LLY, and SKYE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVO, LLY, and SKYE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVO, LLY, and SKYE Company Descriptions

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

Skye Bioscience NASDAQ:SKYE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools